Trial Profile

Phase II Study of Docetaxel, Oxaliplatin, Capecitabine With Bevacizumab and Trastuzumab in Case of Human Epidermal Growth Factor Receptor 2 (HER2)-Positivity in Patients With Locally Advanced or Metastatic Gastric Cancer or Adenocarcinoma of the Gastro-oesophageal Junction (B-DOCT Study).

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 05 Jan 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Docetaxel (Primary) ; Oxaliplatin (Primary) ; Trastuzumab (Primary)
Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
Focus Pharmacogenomic; Therapeutic Use
Acronyms B-DOCT

05 Jan 2023 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified Jan 2021).
11 Mar 2016 Results published in the Cancer
17 Mar 2012 Planned end date (19 Jan 2015) added as reported by European Clinical Trials Database.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com